Arrowhead Pharmaceuticals Says Phase 1/2a Interim Single-Dose Data For ARO-DIMER-PA Showed Mean Maximal Reductions Of 54% In Bad Cholesterol, 73% In Triglycerides; No Drug-Related Serious Adverse Events

Loading news article.

Arrowhead Pharmaceuticals Says Phase 1/2a Interim Single-Dose Data For ARO-DIMER-PA Showed Mean Maximal Reductions Of 54% In Bad Cholesterol, 73% In Triglycerides; No Drug-Related Serious Adverse Events | WAPE

Arrowhead Pharmaceuticals Says Phase 1/2a Interim Single-Dose Data For ARO-DIMER-PA Showed Mean Maximal Reductions Of 54% In Bad Cholesterol, 73% In Triglycerides; No Drug-Related Serious Adverse Events

Article summary

Related companies

Comments —